tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cidara Therapeutics downgraded to Neutral from Buy at Guggenheim
PremiumThe FlyCidara Therapeutics downgraded to Neutral from Buy at Guggenheim
2M ago
Merck expects over $5B opportunity from Cidara’s flu drug, Reuters reports
Premium
The Fly
Merck expects over $5B opportunity from Cidara’s flu drug, Reuters reports
2M ago
Cidara Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Premium
The Fly
Cidara Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
2M ago
Cidara Therapeutics downgraded to Hold from Buy at Needham
PremiumThe FlyCidara Therapeutics downgraded to Hold from Buy at Needham
2M ago
Cidara Therapeutics rises 105.6%
Premium
The Fly
Cidara Therapeutics rises 105.6%
2M ago
Cidara Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Cidara Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
2M ago
Merck to acquire Cidara Therapeutics for $221.50 per share in cash, or $9.2B
PremiumThe FlyMerck to acquire Cidara Therapeutics for $221.50 per share in cash, or $9.2B
2M ago
Cidara Therapeutics jumps 104% to $216.26 after Merck buyout offer
Premium
The Fly
Cidara Therapeutics jumps 104% to $216.26 after Merck buyout offer
2M ago
Merck close to deal to acquire Cidara Therapeutics, FT reports
Premium
The Fly
Merck close to deal to acquire Cidara Therapeutics, FT reports
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100